

Analytical Performance Evaluation versus Cobas Integra 800

Published: 28-04-2008

Last updated: 11-05-2024

Barst maar!

Ethical review	Approved WMO
Status	Pending
Health condition type	Glucose metabolism disorders (incl diabetes mellitus)
Study type	Observational invasive

Summary

ID

NL-OMON32286

Source

ToetsingOnline

Brief title

Quotient HbA1c

Condition

- Glucose metabolism disorders (incl diabetes mellitus)

Synonym

Diabetes

Research involving

Human

Sponsors and support

Primary sponsor: Roche Diagnostics

Source(s) of monetary or material Support: Roche Diagnostics

Intervention

Keyword: analytical performance, bias, HbA1c, Linearity

Outcome measures

Primary outcome

Barst maar!

Secondary outcome

Barst maar!

Study description

Background summary

Barst maar!

Study objective

Barst maar!

Study design

Barst maar!

Study burden and risks

Barst maar!

Contacts

Public

Roche Diagnostics

Sandhofer Strasse 166
D-68305 Mannheim
Duitsland

Scientific

Roche Diagnostics

Sandhofer Strasse 166
D-68305 Mannheim

Duitsland

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years)

Elderly (65 years and older)

Inclusion criteria

Diabetes

Exclusion criteria

nvt

Study design

Design

Study type: Observational invasive

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Diagnostic

Recruitment

NL

Recruitment status: Pending

Start date (anticipated): 01-05-2008

Enrollment: 60
Type: Anticipated

Ethics review

Approved WMO
Date: 28-04-2008
Application type: First submission
Review commission: METC Isala Klinieken (Zwolle)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
CCMO	NL22899.075.08